Show simple item record

dc.contributor.authorOry, Fernando de 
dc.contributor.authorSanchez-Seco, Paz 
dc.contributor.authorVazquez, Ana 
dc.contributor.authorMontero, María Dolores
dc.contributor.authorSulleiro, Elena
dc.contributor.authorMartínez, Miguel J
dc.contributor.authorMatas, Lurdes
dc.contributor.authorMerino, Francisco J
dc.identifier.citationViruses. 2018 Jul 19;10(7). pii: E379.es_ES
dc.description.abstractDifferential diagnosis of the Zika virus (ZIKV) is hampered by cross-reactivity with other flaviviruses, mainly dengue viruses. The aim of this study was to compare two commercial methods for detecting ZIKV immunoglobulin M (IgM), an indirect immunofluorescence (IIF) and an enzyme immunoassay (ELISA), using the non-structural (NS) 1 protein as an antigen, both from EuroImmun, Germany. In total, 255 serum samples were analyzed, 203 of which showed laboratory markers of ZIKV infections (PCR-positive in serum and/or in urine and/or positive or indeterminate specific IgM). When tested with IIF, 163 samples were IgM-positive, while 13 samples were indeterminate and 78 were negative. When IIF-positive samples were tested using ELISA, we found 61 positive results, 14 indeterminate results, and 88 negative results. Among the indeterminate cases tested with IIF, ELISA analysis found two positive, two indeterminate, and nine negative results. Finally, 74 of the 78 IIF-negative samples proved also to be negative using ELISA. For the calculations, all indeterminate results were considered to be positive. The agreement, sensitivity, and specificity between ELISA and IIF were 60.2%, 44.9%, and 94.9%, respectively. Overall, 101 samples showed discrepant results; these samples were finally classified on the basis of other ZIKV diagnostic approaches (PCR-positive in serum and/or in urine, IgG determinations using IIF or ELISA, and ZIKV Plaque Reduction Neutralization test-positive), when available. A final classification of 228 samples was possible; 126 of them were positive and 102 were negative. The corresponding values of agreement, sensitivity, and specificity of IIF were 86.0%, 96.8%, and 72.5%, respectively. The corresponding figures for ELISA were 81.1%, 65.9%, and 100%, respectively. The ELISA and IIF methods are both adequate approaches for detecting ZIKV-specific IgM. However, considering their respective weaknesses (low sensitivity in ELISA and low specificity in IIF), serological results must be considered jointly with other laboratory results.es_ES
dc.description.sponsorshipThe study was partially financed by a contract between the ISCIII and Euroimmun Diagnostics España SLU (MVP216/17), and by ISCIII, project RD16CIII/0003/0003, “Red de Enfermedades Tropicales”, Subprogram RETICS Plan Estatal de I+D+I 2013-2016, and co-funded by FEDER “Una manera de hacer Europa” and project PI16CIII/00037.es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectZika viruses_ES
dc.subjectdengue viruseses_ES
dc.subjectindirect immunofluorescencees_ES
dc.subjectplaque reduction neutralization testes_ES
dc.subjectpolymerase chain reactiones_ES
dc.subject.meshAdult es_ES
dc.subject.meshAntibodies, Viral es_ES
dc.subject.meshCross Reactions es_ES
dc.subject.meshDengue Virus es_ES
dc.subject.meshDiagnosis, Differential es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGermany es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunoglobulin G es_ES
dc.subject.meshImmunoglobulin M es_ES
dc.subject.meshInfant, Newborn es_ES
dc.subject.meshMale es_ES
dc.subject.meshNeutralization Tests es_ES
dc.subject.meshPolymerase Chain Reaction es_ES
dc.subject.meshPregnancy es_ES
dc.subject.meshReagent Kits, Diagnostices_ES
dc.subject.meshSensitivity and Specificity es_ES
dc.subject.meshViral Nonstructural Proteins es_ES
dc.subject.meshZika Virus es_ES
dc.subject.meshZika Virus Infection es_ES
dc.subject.meshEnzyme-Linked Immunosorbent Assay es_ES
dc.subject.meshFluorescent Antibody Technique, Indirect es_ES
dc.titleComparative Evaluation of Indirect Immunofluorescence and NS-1-Based ELISA to Determine Zika Virus-Specific IgMes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderRed de Investigación Cooperativa en Enfermedades Tropicales (España)es_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional